Anti-Albuminuric Effects of the Angiotensin AT1 Receptor Blocker Telmisartan in Hypertensive Patients

• Published in: Clinical and experimental hypertension (1993) Vol. 33; no. 8; pp. 506 - 510
• Main Authors: Rodríguez-Pérez, José C., García-Bello, Miguel A., Anabitarte-Prieto, Aránzazu, Companioni, Osmel, Nóvoa-Mogollón, Francisco J., Suárez-Ortega, Saturnino, Plaza-Toledano, Celia, Rodríguez-Esparragón, Francisco
• Format: Journal Article
• Language: English
• Published: England Informa Healthcare 01.12.2011; Taylor & Francis
• Subjects: Adult; Aged; Aged, 80 and over; albuminuria; Albuminuria - drug therapy; Amlodipine - administration & dosage; Angiotensin II Type 1 Receptor Blockers - administration & dosage; Antihypertensive Agents - administration & dosage; Benzimidazoles - administration & dosage; Benzoates - administration & dosage; Blood Pressure - drug effects; Creatinine - blood; diabetes mellitus; Diabetic Nephropathies - drug therapy; Drug Therapy, Combination; Female; Glomerular Filtration Rate - drug effects; Humans; hypertension; Hypertension, Renal - drug therapy; Male; Middle Aged; Prospective Studies; renoprotection; Sulfonamides - administration & dosage; telmisartan; Treatment Outcome
• ISSN: 1064-1963; 1525-6006
• DOI: 10.3109/10641963.2011.561900

We evaluated the anti-hypertensive and anti-albuminuric effect of the angiotensin receptor blocker telmisartan alone and in combination with torasemide and amlodipine. Patients were hypertensive, both diabetics and non-diabetics with persistent microalbuminuria. Our primary endpoint was a change in microalbuminuria levels, while the secondary endpoints were changes in systolic blood pressure (SBP), diastolic blood pressure (DBP), serum creatinine levels, and glomerular filtration rate.After the 16-week treatment period, the patients significantly reduced microalbuminuria levels (76.4 ± 52.4 μg/min; p < 0.001), SBP (16.4 ± 8.7 mmHg; p < 0.001) and DBP (17.7 ± 5.9 mmHg; p < 0.001). Both diabetics and non-diabetics showed an identical pattern of significance with respect to the whole population. Systolic blood pressure, DBP, and microalbuminuria were significantly reduced as a consequence of therapy, both in diabetics and non-diabetics.